翰森制药 | 圣罗莱®两项研究成果亮相ASN 2025，心血管安全性优势再添力证

1.Zhang, Xinyu,et al.Pegmolesatide Ameliorates Indoxyl Sulfate-Induced Cardiomyocyte Hypertrophy Through Modulating the EPOR-CD131-Dependent JAK2/STAT3 Signaling Pathway. ASN 2025. Abstract: TH-PO0288

2.Chen Jianghua, et al. Efficacy and Cardiovascular Safety of Pegmolesatide in Renal Anemia: Post Hoc Analysis of Two Phase 3 Trials. ASN 2025. Abstract: FR-PO0199

3.Zhang X, Li S, Lin T,et al.Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway.Int Immunopharmacol. 2025 Oct 14;167:115643.

4.Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28; 65:102273

5.Xie J, et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney Int Rep. 2024 Dec 6;10(3):720-729.

6.Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888

7.中国肾性贫血诊治临床实践指南. 中华医学杂志,2021,101(20):1463-1502.

8.Palmer SC, et al.Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 6;153(1):23-33.

9.长效红细胞生成刺激剂治疗肾性贫血中国专家共识（2024年版）. 中华肾脏病杂志,2024,40(2):146-157.

10.指导肾性贫血患者自我管理的中国专家共识(2024 版). 中国血液净化.2025,24(1):1-12

11.延缓慢性肾脏病进展临床管理指南（2025年版）. 中华肾脏病杂志,2025,41(6):455-488.